← Back to Search

Bronchodilator

COPD group for Chronic Obstructive Pulmonary Disease (CODEx Trial)

N/A
Waitlist Available
Led By François Maltais, M.D
Research Sponsored by Laval University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline at the end of the exercise.
Awards & highlights

CODEx Trial Summary

During the previous phases of the project (Phase I and II), two new field tests have been designed and validated for an integration in a primary care setting in Chronic Obstructive Pulmonary Disease (COPD). These new field tests are 3-min paced-walk test (3MPWT) and 3-min paced step test (3MPST). If the validity and sensitivity of the TM3 could be highlighted, particularly by the reduction of dyspnea level following bronchodilatation, Phase II highlight that the 3MPST does not allow to detect this decrease of dyspnea after bronchodilatation. The use of too high step rates could explain these results through a hypothesis relative to neuromechanical coupling of dyspnea. The main objective of this trial is to follow the investigations on the sensitivity of 3MPST to detect the effects of pharmacological intervention on the exertional dyspnea in COPD patient. The hypothesis of this work is that the use of lower step rates cadences could allow to detect an improvement of exertional dyspnea following treatment-induced bronchodilatation, contrary to higher step rates.

Eligible Conditions
  • Chronic Obstructive Pulmonary Disease
  • Shortness of Breath

CODEx Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline at 1, 2 and 3 minutes of exercise
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline at 1, 2 and 3 minutes of exercise for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Symptom perception
Secondary outcome measures
Cardiac and ventilatory outcomes
Inspiratory capacity
Maximal inspiratory pressure (PImax)
+3 more

CODEx Trial Design

1Treatment groups
Experimental Treatment
Group I: COPD groupExperimental Treatment1 Intervention
Moderate and/or severe COPD patients, corresponding to GOLD stages II and III.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Combination ipratropium/salbutamol or placebo (nebulization)
2009
N/A
~60

Find a Location

Who is running the clinical trial?

Laval UniversityLead Sponsor
417 Previous Clinical Trials
172,232 Total Patients Enrolled
Université de MontréalOTHER
213 Previous Clinical Trials
102,681 Total Patients Enrolled
François Maltais, M.DPrincipal InvestigatorInstitut universitaire de cardiologie et de pneumologie de Québec, University Laval

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Apr 2025